Serum Institute of India

Bhubaneshwar, India

Serum Institute of India

Bhubaneshwar, India

Time filter

Source Type

Low N.,University of Bern | Bavdekar A.,King Edward Memorial Hospital Research Center | Jeyaseelan L.,Christian Medical College | Hirvez S.,Shirdi Sai Baba Hospital | And 15 more authors.
New England Journal of Medicine | Year: 2015

BACKGROUND: Aerosolized vaccine can be used as a needle-free method of immunization against measles, a disease that remains a major cause of illness and death. Data on the immunogenicity of aerosolized vaccine against measles in children are inconsistent. METHODS: We conducted an open-label noninferiority trial involving children 9.0 to 11.9 months of age in India who were eligible to receive a first dose of measles vaccine. Children were randomly assigned to receive a single dose of vaccine by means of either aerosol inhalation or a subcutaneous injection. The primary end points were seropositivity for antibodies against measles and adverse events 91 days after vaccination. The noninferiority margin was 5 percentage points. RESULTS: A total of 1001 children were assigned to receive aerosolized vaccine, and 1003 children were assigned to receive subcutaneous vaccine; 1956 of all the children (97.6%) were followed to day 91, but outcome data were missing for 331 children because of thawed specimens. In the per-protocol population, data on 1560 of 2004 children (77.8%) could be evaluated. At day 91, a total of 662 of 775 children (85.4%; 95% confidence interval [CI], 82.5 to 88.0) in the aerosol group, as compared with 743 of 785 children (94.6%; 95% CI, 92.7 to 96.1) in the subcutaneous group, were seropositive, a difference of -9.2 percentage points (95% CI, -12.2 to -6.3). Findings were similar in the full-analysis set (673 of 788 children in the aerosol group [85.4%] and 754 of 796 children in the subcutaneous group [94.7%] were seropositive at day 91, a difference of -9.3 percentage points [95% CI, -12.3 to -6.4]) and after multiple imputation of missing results. No serious adverse events were attributable to measles vaccination. Adverse-event profiles were similar in the two groups. CONCLUSIONS: Aerosolized vaccine against measles was immunogenic, but, at the prespecified margin, the aerosolized vaccine was inferior to the subcutaneous vaccine with respect to the rate of seropositivity. (Funded by the Bill and Melinda Gates Foundation; Measles Aerosol Vaccine Project Clinical Trials Registry-India number, CTRI/ 2009/ 091/ 000673.) Copyright © 2015 Massachusetts Medical Society.


Ganu G.P.,Dr D Y Patil Institute Of Pharmaceutical Science And Research | Jadhav S.S.,Serum Institute of India | Deshpande A.D.,Dr D Y Patil Institute Of Pharmaceutical Science And Research
International Journal of Phytomedicine | Year: 2010

Ayurveda refers Mimusops elengi L. for the treatment of the diabetes. Considering the traditional claim of M. elengi in management of diabetes and the possible involvement of oxidative stress in pathogenesis of diabetes, the present study was aimed to evaluate the in vitro antioxidant and in vivo antihyperglycemic property of methanolic extract of bark of M. elengi (MEMeOH). In vitro antioxidant activity of MEMeOH was evaluated using reducing power assay, DPPH and hydroxyl radical scavenging assay. MEMeOH offered significant in vitro reducing power capacity and radical scavenging activity. In acute study in alloxan induced diabetes, MEMeOH exhibited significant (p< 0.001) antihyperglycemic effect. The onset of antihyperglycemic effect was observed at 2nd hr; peak activity was demonstrated at 6th hr. The antihyperglycemic effect of MEMeOH 400mg/kg, p.o. was persistent up to 24th hr after drug administration. MEMeOH produced significant (p < 0.01) reduction in elevated glucose levels in glucose loaded non diabetic animals. The onset of action in non diabetic oral glucose tolerance test was found to be at 60th min and peak activity was observed at 120th min after oral glucose load. MEMeOH demonstrated significant (p < 0.01) reduction in elevated glucose levels 2hr before glucose administration and 6 hr after glucose load in oral glucose tolerance test in diabetic animals. MEMeOH has demonstrated antihyperglycemic activity in diabetic as well as non diabetic glucose loaded mice. MEMeOH should be further explored against diabetes and related complications. © arjournals.org, All rights reserved.


News Article | November 2, 2016
Site: www.newsmaker.com.au

MarketStudyReport.com adds “Global H1N1 Vaccines Market 2016-2020” new report to its research database. The report spread across 83 pages with table and figures in it. The Research analysts forecast the global H1N1 vaccines market to grow at a CAGR of 4.17% during the period 2016-2020. The high level of maturity in the H1N1 vaccines market has renewed the push to develop quadrivalent vaccines that address areas of the market with unmet medical needs. Vaccines that prevent H1N1 have been a long-standing void in the treatment algorithm. Therefore, the introduction advanced vaccines in the next decade will likely alter the global H1N1 vaccines market landscape. Sanofi, AstraZeneca, and VaxInnate have also invested in quadrivalent vaccines, such as Sanofi's VaxiGrip, VaxInnate's VAX2012Q, and AstraZeneca's MEDI-550 vaccine, which will impact the US and Europe markets during the forecast period. Other areas of opportunity for novel entrants include vaccines with improved immune response and immunogenic infant vaccines. Browse full table of contents and data tables at https://www.marketstudyreport.com/reports/global-h1n1-vaccines-market-2016-2020/ Covered in this report The report covers the present scenario and the growth prospects of the global H1N1 vaccines market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of vaccines used to prevent H1N1 infection. The report also considers the revenues to be generated from the sales of vaccines that are expected to be launched into the market during the forecast period. The market is divided into the following segments based on geography: - Americas - APAC - EMEA The Research report, Global H1N1 Vaccines Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Key vendors - Sanofi - GSK - Astra Zeneca - CSL Other prominent vendors - Abbott - Baxter International - CEL-SCI - Cipla - Crucell - Denka Seiken - Green Cross - Hualan Biological Engineering - iBio - Imunoloski Zavod - Inovio Biomedical - Lupin - Medicago USA - Merck - Mitsubishi Tanabe Pharma - Omnivest - Panacea - Pfizer - Protein Sciences - Serum Institute of India - Sinovac Biotech - Solvay - Zhejiang Tianyuan Bio-pharmaceuticals - Zydus Cadila Market driver - Global action plan for influenza vaccines - For a full, detailed list, view our report Market challenge - Vaccine storage and handling issues - For a full, detailed list, view our report Market trend - Improved understanding of immunology - For a full, detailed list, view our report Key questions answered in this report - What will the market size be in 2020 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? To receive personalized assistance write to us @ [email protected] with the report title in the subject line along with your questions or call us at +1 866-764-2150


News Article | December 28, 2016
Site: marketersmedia.com

The analysts forecast the global human vaccines market to grow at a CAGR of 11.69% during the period 2016-2020. According to the Centers for Disease Control and Prevention (CDC), a vaccine is a product that stimulates a person’s immune system to produce immunity to a specific disease, protecting the person from that disease. Vaccines are usually administered through needle injections, but can also be administered by mouth or sprayed into the nose. Human vaccines are of two types: preventable human vaccines and therapeutic human vaccines. Preventable human vaccines are used both for adults and children. Pediatric human vaccines are used to immunize children against various infectious diseases such as diphtheria, influenza, hepatitis, pneumococcal diseases, and meningococcal diseases. For more information or any query mail at sales@wiseguyreports.com The report covers the present scenario and the growth prospects of the global human vaccines market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of preventable and therapeutic human vaccines. The market is divided into the following segments based on geography: • Americas • APAC • Europe The report, Global Human Vaccine Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Other prominent vendors • Abbott • AstraZeneca • Bavarian Nordic • Baxter • Bharat Biotech • Bharat Immunologicals and Biologicals • bioCSL • Bio Med • Crucell • Dynavax Technologies • Indian Immunologicals • Janssen Pharmaceuticals • Kaketsuken • LG Life Sciences • Mitsubishi Tanabe Pharma • Lupin • Nuron • Novartis • Protein Sciences Corporation • Panacea Biotec • Roche • Serum Institute of India • Shenzhen Kangtai Biological Products • Sinovac Biotech • S K Chemicals • Takeda Pharmaceutical • Valeant Pharmaceuticals • Zydus Cadila Market driver • Growing awareness about vaccination and immunization programs • For a full, detailed list, view our report Market trend • Increase in strategic alliance and M&A • For a full, detailed list, view our report Key questions answered in this report • What will the market size be in 2020 and what will the growth rate be? • What are the key market trends? • What is driving this market? • What are the challenges to market growth? • Who are the key vendors in this market space? • What are the market opportunities and threats faced by the key vendors? • What are the strengths and weaknesses of the key vendors? For more information or any query mail at sales@wiseguyreports.com ABOUT US: Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories. For more information, please visit https://www.wiseguyreports.com


News Article | November 9, 2016
Site: www.newsmaker.com.au

The report provides comprehensive information on the therapeutics under development for Rotavirus Infections  ,complete with analysis by stage of development,drug target,mechanism of action (MoA),route of administration (RoA) and molecule type. The report also coversthe descriptive pharmacological action of the therapeutics,its complete research and development history and latest news and press releases. Additionally,the report provides an overview of key players involved in therapeutic development for Rotavirus Infections   and features dormant and discontinued projects. The report helps in identifying and tracking emerging players in the market and their portfolios,enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete report on Rotavirus Infections - Pipeline Review,H2 2016 addition with 26 market data tables and 13 figures, spread across 62 pages is available at http://www.rnrmarketresearch.com/rotavirus-infections-pipeline-review-h2-2016-market-report.html This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases,company/university websites,clinical trial registries,conferences,SEC filings,investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally,various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Beijing Minhai Biotechnology Co., Ltd,Bharat Biotech International Limited,Biological E. Limited,Curevac AG ,Medicago Inc. ,MSD Wellcome Trust Hilleman Laboratories Pvt Ltd,Nanotherapeutics, Inc.,Serum Institute of India Limited,Shantha Biotechnics Limited,Sinovac Biotech Ltd.,Takeda Pharmaceutical Company Limited,Wuhan Institute of Biological Products Co., Ltd. Inquire before buying http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=748014(This is a premium report price at US$2000 for a single user PDF license).


News Article | November 30, 2016
Site: www.newsmaker.com.au

This analyst forecast the global travel vaccines market to grow at a CAGR of 6.83% during the period 2016-2020.Global Travel Vaccines Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. This report covers the present scenario and the growth prospects of the global travel vaccines market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of various vaccines administered to actively immunize meningococcal disease, Japanese encephalitis, rabies, typhoid, yellow fever, hepatitis B, and hepatitis A. The report also considers the revenues to be generated from the sales of vaccines that are expected to be launched into the market during the forecast period. The following companies are the key players in the global travel vaccines market: GlaxoSmithKline, Merck, Pfizer, and Sanofi. Other Prominent Vendors in the market are: Abbott, AstraZeneca, Bavarian Nordic, Baxter, Beijing Minhai Biotechnology, Bharat Biotech, Bharat Immunologicals and Biologicals, Bio-Med, Seqirus CSL, Crucell, CSL, Dynavax Technologies, Emergent BioSolutions, GlycoVaxyn, GreenSignal Bio Pharma, Hualan Biological Engineering, Imunoloski Zavod, Indian Immunologicals, Janssen Pharmaceuticals, JN International Medical, Kaketsuken, LG Life Sciences, Lupin, Mitsubishi Tanabe Pharma, Novavax, Nuron Biotech, Panacea Biotec, Pfizer, Protein Sciences, Roche, SK Chemicals, Serum Institute of India, Shenzhen Kangtai Biological Products, Sinovac Biotech, Takeda Pharmaceutical, Vacunas Finlay, Valeant Pharmaceuticals, Valneva, and Zydus Cadila. The market is divided into the following segments based on geography: Commenting on the report, an analyst said: "R&D is budding due to a strong need for new efficacious and better tolerated vaccines. The market presents huge growth potential for vendors because of the growing incidence of infectious disease. This requirement is creating a demand for novel vaccines where major players are focusing their R&D efforts and once launched, should become the major growth drivers. Increased investment in R&D by major pharmaceutical companies would fuel the growth of the global travel vaccines market." According to the report, the growing demand for vaccines among international travelers is one of the major factors driving the market growth. Many international and national bodies have mandated that the immigrants should be vaccinated before traveling to disease-prone areas. Considering vaccines are largely perceived as a prevention mechanism against the spread of any infectious disease; it is making a specific requirement in international traveler's list.


WiseGuyReports.Com Publish a New Market Research Report On – “Travel Vaccines Market by Manufacturers,Types,Regions and Applications Research Report Forecast to 2020”. The analysts forecast the global travel vaccines market to grow at a CAGR of 6.83% during the period 2016-2020. As the world continues to move toward globalization, the international travels will keep increasing. This fuels the demand for travel vaccines as the prevalence of infectious diseases are specifically region prone, unlike that of other indications. As vaccines are largely used as a preventive measure against these known infectious diseases, the travelers are advised to follow the region-specific immunization plan. The market is growing because various government bodies have mandated the immunization of travelers visiting the infectious-prone areas with various types of vaccines. This, in turn, prevents the spread of infection and averts any chances of epidemic outbreaks. For more information or any query mail at [email protected] Covered in this report  The report covers the present scenario and the growth prospects of the global travel vaccines market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of various vaccines administered to actively immunize meningococcal disease, Japanese encephalitis, rabies, typhoid, yellow fever, hepatitis B, and hepatitis A. The report also considers the revenues to be generated from the sales of vaccines that are expected to be launched into the market during the forecast period. The market is divided into the following segments based on geography:  • Americas  • APAC  • EMEA The report, Global Travel Vaccines Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Other prominent vendors  • Abbott  • AstraZeneca  • Bavarian Nordic  • Baxter  • Beijing Minhai Biotechnology  • Bharat Biotech  • Bharat Immunologicals and Biologicals  • Bio-Med  • Seqirus CSL  • Crucell  • CSL  • Dynavax Technologies  • Emergent BioSolutions  • GlycoVaxyn  • GreenSignal Bio Pharma  • Hualan Biological Engineering  • Imunoloski Zavod  • Indian Immunologicals  • Janssen Pharmaceuticals  • JN International Medical  • Kaketsuken  • LG Life Sciences  • Lupin  • Mitsubishi Tanabe Pharma  • Novavax  • Nuron Biotech  • Panacea Biotec  • Pfizer  • Protein Sciences  • Roche  • SK Chemicals  • Serum Institute of India  • Shenzhen Kangtai Biological Products  • Sinovac Biotech  • Takeda Pharmaceutical  • Vacunas Finlay  • Valeant Pharmaceuticals  • Valneva,  • Zydus Cadila Market driver  • Growing demand among travelers  • For a full, detailed list, view our report Market challenge  • Requires specific storage and distribution system  • For a full, detailed list, view our report Key questions answered in this report  • What will the market size be in 2020 and what will the growth rate be?  • What are the key market trends?  • What is driving this market?  • What are the challenges to market growth?  • Who are the key vendors in this market space?  • What are the market opportunities and threats faced by the key vendors?  • What are the strengths and weaknesses of the key vendors? PART 09: Geographical segmentation  • Travel vaccines market in Americas  • Travel vaccines market in EMEA  • Travel vaccines market in APAC PART 11: Impact of drivers  PART 12: Market challenges  • Requires specific storage and distribution system  • High risk and cost involved in vaccine development  • Stringent regulatory guidelines For more information or any query mail at [email protected] Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.


MarketStudyReport.com adds “Global Travel Vaccines Market 2016-2020” new report to its research database. The report spread across 60 pages with table and figures in it. The Report analysts forecast the global travel vaccines market to grow at a CAGR of 6.83% during the period 2016-2020. About Travel Vaccines As the world continues to move toward globalization, the international travels will keep increasing. This fuels the demand for travel vaccines as the prevalence of infectious diseases are specifically region prone, unlike that of other indications. As vaccines are largely used as a preventive measure against these known infectious diseases, the travelers are advised to follow the region-specific immunization plan. The market is growing because various government bodies have mandated the immunization of travelers visiting the infectious-prone areas with various types of vaccines. This, in turn, prevents the spread of infection and averts any chances of epidemic outbreaks. Browse full table of contents and data tables at https://www.marketstudyreport.com/reports/global-travel-vaccines-market-2016-2020/ The report covers the present scenario and the growth prospects of the global travel vaccines market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of various vaccines administered to actively immunize meningococcal disease, Japanese encephalitis, rabies, typhoid, yellow fever, hepatitis B, and hepatitis A. The report also considers the revenues to be generated from the sales of vaccines that are expected to be launched into the market during the forecast period. The market is divided into the following segments based on geography:  Americas APAC EMEA The Report Global Travel Vaccines Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Key vendors  GlaxoSmithKline Merck Pfizer Sanofi Other prominent vendors  Abbott AstraZeneca Bavarian Nordic Baxter Beijing Minhai Biotechnology Bharat Biotech Bharat Immunologicals and Biologicals Bio-Med Seqirus CSL Crucell CSL Dynavax Technologies Emergent BioSolutions GlycoVaxyn GreenSignal Bio Pharma Hualan Biological Engineering Imunoloski Zavod Indian Immunologicals Janssen Pharmaceuticals JN International Medical Kaketsuken LG Life Sciences Lupin Mitsubishi Tanabe Pharma Novavax Nuron Biotech Panacea Biotec Pfizer Protein Sciences Roche SK Chemicals Serum Institute of India Shenzhen Kangtai Biological Products Sinovac Biotech Takeda Pharmaceutical Vacunas Finlay Valeant Pharmaceuticals Valneva, Zydus Cadila Market driver  Growing demand among travelers  For a full, detailed list, view our report  Market challenge  Requires specific storage and distribution system  For a full, detailed list, view our report  Market trend  Combination vaccines For a full, detailed list, view our report  Key questions answered in this report  What will the market size be in 2020 and what will the growth rate be? What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors in this market space? What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors? To receive personalized assistance, write to us @ [email protected] with the report title in the subject line along with your questions or call us at +1 866-764-2150


News Article | December 2, 2016
Site: www.prnewswire.co.uk

The global travel vaccines market analyst says R&D is budding due to a strong need for new efficacious and better tolerated vaccines. The market presents huge growth potential for vendors because of the growing incidence of infectious disease. This requirement is creating a demand for novel vaccines where major players are focusing their R&D efforts and once launched, should become the major growth drivers. Increased investment in R&D by major pharmaceutical companies would fuel the growth of the global travel vaccines market. Complete report on travel vaccines market spread across 60 pages, analysing 4 major companies and providing 64 data exhibits now available at http://www.reportsnreports.com/reports/769803-global-travel-vaccines-market-2016-2020.html. This analyst forecast the global travel vaccines market to grow at a CAGR of 6.83% during the period 2016-2020. According to the travel vaccines market report, the growing demand for vaccines among international travellers is one of the major factors driving the market growth. Many international and national bodies have mandated that the immigrants should be vaccinated before traveling to disease-prone areas. Considering vaccines are largely perceived as a prevention mechanism against the spread of any infectious disease; it is making a specific requirement in international traveller's list. The Americas was the highest revenue contributing region in the travel vaccines market during 2015 and will continue to lead the market in the coming years. The US was one of the highest revenue contributors in the region, capturing a significant portion of the global market. The increasing demand for vaccines that cater to the unmet medical needs provides an opportunity for vendors to develop new safe and efficient molecules, which will aid in the growth of travel vaccines market in the region. The combination vaccines segment is one of the fastest growing segments of the travel vaccines market. These vaccines confer protection against different causative agents for diseases such as meningitis, measles, rubella, mumps, diphtheria, pertussis, and tetanus. The following companies are the key players in the global travel vaccines market: GlaxoSmithKline, Merck, Pfizer, and Sanofi. Other prominent vendors in the market are: Abbott, AstraZeneca, Bavarian Nordic, Baxter, Beijing Minhai Biotechnology, Bharat Biotech, Bharat Immunologicals and Biologicals, Bio-Med, Seqirus CSL, Crucell, CSL, Dynavax Technologies, Emergent BioSolutions, GlycoVaxyn, GreenSignal Bio Pharma, Hualan Biological Engineering, Imunoloski Zavod, Indian Immunologicals, Janssen Pharmaceuticals, JN International Medical, Kaketsuken, LG Life Sciences, Lupin, Mitsubishi Tanabe Pharma, Novavax, Nuron Biotech, Panacea Biotec, Pfizer, Protein Sciences, Roche, SK Chemicals, Serum Institute of India, Shenzhen Kangtai Biological Products, Sinovac Biotech, Takeda Pharmaceutical, Vacunas Finlay, Valeant Pharmaceuticals, Valneva, and Zydus Cadila. Order a copy of Global Travel Vaccines Market 2016-2020 report @ http://www.reportsnreports.com/purchase.aspx?name=769803. Global Travel Vaccines Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the present scenario and the growth prospects of the global travel vaccines market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of various vaccines administered to actively immunize meningococcal disease, Japanese encephalitis, rabies, typhoid, yellow fever, hepatitis B, and hepatitis A. The report also considers the revenues to be generated from the sales of vaccines that are expected to be launched into the market during the forecast period. Another related report is Global Human Vaccine Market 2016-2020, a major trend being witnessed in the global human vaccines market is the increase in strategic alliances. Increase in threat from regional vendors in developing countries may cause price erosion and may compel major players to operate under low-margin models. M&A are usually intended to increase the market penetration of the acquirer or to enhance the product portfolio of the parent company. Browse complete report @ http://www.reportsnreports.com/reports/461270-global-human-vaccine-market-2016-2020.html. Explore other new reports on Pharmaceuticals Market @ http://www.reportsnreports.com/market-research/pharmaceuticals/. ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. Connect With Us on:


News Article | October 25, 2016
Site: news.yahoo.com

The UNICEF logo is pictured on a building in Geneva November 17, 2009. REUTERS/Denis Balibouse/Files GENEVA (Reuters) - The United Nations Children's Fund (UNICEF) said on Wednesday it had reached an agreement with six vaccine suppliers to provide a combined vaccine against five deadly childhood diseases for half the price it currently pays. An estimated 5.7 million deaths a year could be averted under the deal to send 450 million doses to 80 countries between 2017-2020, the agency added. "We will be able to procure pentavalent vaccine to protect children ... for less than $1 a dose," Shanelle Hall, director of UNICEF's supply and procurement division, told a news briefing. The vaccine, a cornerstone of routine immunisation programmes, will protect children from five major infections in one shot: diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenza type b known as Hib - a bacteria that causes meningitis, pneumonia and otitis. The six suppliers were named as: Biology E, Jenssen, LG Life Sciences <068870.KS>, Panacea Biotec Ltd , Serum Institute of India, and Shantha Biotechs. The deal, which took 16 years to reach, will bring down the average price to 85 cents a dose, half the amount that UNICEF currently pays, generating savings for donors and governments. It took time to expand a base of vaccine suppliers, which will reduce the risk of shortages, GAVI, the Vaccine Alliance said in a statement. GAVI and the Gates Foundation joined UNICEF in securing the multi-year suppliers' contract.

Loading Serum Institute of India collaborators
Loading Serum Institute of India collaborators